Description

Cultrex®HumanFibronectin,Pathclear®ispurifiedfromhumanplasmaandisPathclear®certifiedtobefreeofcommonpathogens.Fibronectinisanextracellularmatrixproteinthatisfoundabundantlyinbloodandconnectivetissues.Thesematricesareassociatedwiththeepithelialtomesenchymaltransitionofmetastaticcells–includingtumorcellswithstemcell-likeproperties.Fibronectinperformsessentialfunctionsincollagenfibrillogenesis,aseitherageneralcelladhesionmoleculeoramodulatorinbindingbetweencellsurfacesandtheextracellularmatrix.Fibronectinmatrixassemblyisessentialfornormalvertebratedevelopmentandapparentlycontributestothegenerationoftumormetastasesbysupportingtheestablishmentandpersistenceofpre-metastaticniches.Fibronectinissecretedasadisulfide-linkeddimerof230-270kDa,comprisedofthreetypesofrepeatingmodulesthatmediateinteractionswithextracellularmatrixcomponents(includingfibronectinitself),andcellsviaintegrinsandotherfibronectinreceptors.Thus,fibronectincanbeusedforcoatingtissueculturesurfacesorasamediumadditivetopromotecelladhesionandproliferation;itis0.2μmsterilefiltered.

Cultrex®HumanFibronectin,Pathclear®isapurifiedplasmaextracellularmatrix proteinthathasbeendeveloped,producedandqualifiedspecifically forcellculturestudieswherethepresenceofpathogensmaycauseconcern.

Qualitycontrolspecifications:

• PathClear®–testednegativeforeighthumanpathogenicvirusesincludingHepatitisA,BandC,HIV1and2,Hantaan,Seoul,andSinNombrebyPCR.
• Nobacterialorfungalgrowthdetectedafterincubationat37°Cfor14daysfollowingUSPsterilitytestingguidelines.
• Endotoxinconcentration≤20EU/mlbyLimulusAmoebocyteLysate(LAL)assay.
• Proteinconcentrationof1mg/ml.
• NomycoplasmacontaminationdetectedbyPCR.
• Providedin100mMCAPS,150mMNaCl,1mMCaCI2,pH11.5.
• Purity ≥90%(SDS-PAGE).
• BIOLOGicalactivitydeterminedforeachlot:
  • CellAttachment:TestedfortheABIlitytopromotecellattachmentandspreADIngofHT1080humanfibrosarcomacells.

SafetyStatement:

AlthoughCultrex®HumanFibronectin,PathClear®hasbeentestedforthevirusesaboveitcontainshumansourcematerialandthereforeshouldbetreatedaspotentiallyinfectiousandhandledattheBiologicalSafetyLevel2tominimizeexposure.

DistinctFc{gamma}ReceptorsMediatetheEffectofSerumAmyloidPonNeutrophilAdhesionandFibrocyteDifferentiation
NehemiahCox,DarrellPilling,andRichardH.Gomer
J.Immunol.,Aug2014;193:1701–1708.
http://www.jimmunol.org/cgi/content/abstract/193/4/1701